Abstract
Juvenile-onset Huntington’s disease (JoHD) is a rare, particularly devastating form of Huntington’s Disease (HD) for which clinical diagnosis is challenging and robust outcome measures are lacking. Neurofilament light protein (NfL) in plasma has emerged as a prognostic biomarker for adult-onset HD. We report that plasma NfL is elevated in JoHD and premanifest HD mutation-carrying children. Quantifying plasma NfL may improve clinical diagnosis and therapeutic trial design in the pediatric population.
Competing Interest Statement
LMB, FBR and EJW are full-time UCL employees. LMB receives salary support from the Huntington's disease Society of America, and has provided consultancy for F. Hoffmann-La Roche AG, Genentech, Novartis International AG, Annexon Inc and GLG. JLS receives salary support from the National Center for Advancing Translational Sciences (NIH KL2TR002536) and the Michael J. Fox Foundation for Parkinson's Research. FBR receives salary support from CHDI Foundation, and has provided consultancy to GLG and Roche. E.J.W. reports grants from Medical Research Council UK, CHDI Foundation, and F. Hoffmann-La Roche Ltd. during the conduct of the study and personal fees from F. Hoffman-La Roche Ltd., Triplet Therapeutics, PTC Therapeutics, Shire Therapeutics, Wave Life Sciences, Mitoconix, Takeda Pharmaceuticals Ltd., and Loqus23. All honoraria for these consultancies were paid through the offices of UCL Consultants Ltd., a wholly owned subsidiary of University College London. University College London Hospitals NHS Foundation Trust has received funds as compensation for conducting clinical trials for Ionis Pharmaceuticals, Pfizer, and Teva Pharmaceuticals. and Stroke, the CHDI Foundation, University College of London, and from the Wellcome Trust. During the past 12 months, he has served as a paid statistical consultant for the design of Huntington's Disease trials for Novartis AG, Voyager Therapeutics, Spark therapeutics, and Takeda Pharmaceutical Company Limited. He has also been a paid consultant to Trinity Life Sciences. PN and EVP report no competing interests.
Funding Statement
This work was supported by the Medical Research Council UK (to EJW), the CHDI Foundation (to EJW), the Huntington's Disease Society of America (to LMB), the Hereditary Disease Foundation (to LMB), and the National Institute of Health (NIH) grant NS094387 Growth and Development of the Striatum in Huntington's Disease (to PN).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board at the University of Iowa approved the KidsHD and KidsJoHD studies. The parents or guardians of participants who were less than 18 years old provided written consent and the children provided written assent. Participants who were 18 years or older provided written consent. We combined plasma NfL data from both KidsHD and KidsJoHD with previously published plasma NfL data from the longitudinal HD-CSF cohort to visually assess how NfL fluctuates over the lifespan of the HD mutation carrier. HD-CSF has been extensively described6,11,12 (online protocol: DOI: 10.5522/04/11828448.v1).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
